申请人:BAYER PHARMA AG
公开号:WO2012032031A1
公开(公告)日:2012-03-15
The present invention relates to substituted imidazopyridazine compounds of general formula (l), which are Mps -1 (Monopolar Spindle 1) Kinase inhibitors (also known as Tyrosine Threonine Kinase, TTK) in which R3, R5, and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
本发明涉及通式(l)的取代咪唑吡啶并联化合物,这些化合物是Mps-1(单极纺锤体1)激酶抑制剂(也称为酪氨酸苏氨酸激酶,TTK),其中R3、R5和A如权利要求中所定义,以及制备所述化合物的方法,包括含有所述化合物的药物组合物和配方,以及利用所述化合物制造用于治疗或预防疾病的药物组合物,特别是用作唯一药剂或与其他活性成分组合使用时,用于治疗或预防过度增殖和/或血管生成紊乱。